Molnupiravir in Combination With Nirmatrelvir/Ritonavir: No Cause for Alarm.
作者信息
Kuritzkes Daniel R
机构信息
Division of Infectious Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
出版信息
J Infect Dis. 2024 Dec 16;230(6):1297-1298. doi: 10.1093/infdis/jiae214.
Abstract
摘要
相似文献
1
Molnupiravir in Combination With Nirmatrelvir/Ritonavir: No Cause for Alarm.
J Infect Dis. 2024 Dec 16;230(6):1297-1298. doi: 10.1093/infdis/jiae214.
2
Effectiveness of nirmatrelvir/ritonavir and molnupiravir on post-COVID-19 outcomes among outpatients: a target trial emulation investigation.
Emerg Microbes Infect. 2025 Dec;14(1):2469648. doi: 10.1080/22221751.2025.2469648. Epub 2025 Mar 4.
3
Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.
Cochrane Database Syst Rev. 2023 Nov 30;11(11):CD015395. doi: 10.1002/14651858.CD015395.pub3.
4
Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.
Cochrane Database Syst Rev. 2022 Sep 20;9(9):CD015395. doi: 10.1002/14651858.CD015395.pub2.
5
Real-world effectiveness and economic analysis of nirmatrelvir/ritonavir, remdesivir, and molnupiravir for treatment of COVID-19 among ambulatory patients in Thailand.
J Infect Public Health. 2025 Aug;18(8):102826. doi: 10.1016/j.jiph.2025.102826. Epub 2025 May 13.
6
Analysis of All-Cause Hospitalization and Death Among Nonhospitalized Patients With Type 2 Diabetes and SARS-CoV-2 Infection Treated With Molnupiravir or Nirmatrelvir-Ritonavir During the Omicron Wave in Hong Kong.
JAMA Netw Open. 2023 May 1;6(5):e2314393. doi: 10.1001/jamanetworkopen.2023.14393.
7
Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial.
Lancet Infect Dis. 2024 Jan;24(1):36-45. doi: 10.1016/S1473-3099(23)00493-0. Epub 2023 Sep 28.
8
Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study.
Lancet Infect Dis. 2022 Dec;22(12):1681-1693. doi: 10.1016/S1473-3099(22)00507-2. Epub 2022 Aug 24.
9
Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study.
Lancet. 2022 Oct 8;400(10359):1213-1222. doi: 10.1016/S0140-6736(22)01586-0.
10
Antiviral drug treatment for nonsevere COVID-19: a systematic review and network meta-analysis.
CMAJ. 2022 Jul 25;194(28):E969-E980. doi: 10.1503/cmaj.220471.
本文引用的文献
1
Combined Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 Reduces Molnupiravir-Induced Mutagenicity and Prevents Selection for Nirmatrelvir/Ritonavir Resistance Mutations.
J Infect Dis. 2024 Dec 16;230(6):1380-1383. doi: 10.1093/infdis/jiae213.
2
SARS-CoV-2 Virologic Rebound With Nirmatrelvir-Ritonavir Therapy : An Observational Study.
Ann Intern Med. 2023 Dec;176(12):1577-1585. doi: 10.7326/M23-1756. Epub 2023 Nov 14.
3
Combined molnupiravir-nirmatrelvir treatment improves the inhibitory effect on SARS-CoV-2 in macaques.
JCI Insight. 2023 Feb 22;8(4):e166485. doi: 10.1172/jci.insight.166485.
4
Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir.
Nature. 2023 Jan;613(7944):558-564. doi: 10.1038/s41586-022-05514-2. Epub 2022 Nov 9.
5
Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients.
N Engl J Med. 2022 Feb 10;386(6):509-520. doi: 10.1056/NEJMoa2116044. Epub 2021 Dec 16.
Zotero 插件